In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.
Fintel on MSN14d
JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform RecommendationFintel reports that on January 31, 2025, JMP Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback